Genomeditech has released a new white paper introducing the GM-C41979 Dual-Receptor Reporter Cell Line, a next-generation in-vitro model designed for the evaluation of PD-1–IL-2v fusion biologics. This publication provides detailed background on PD-1/IL-2v mechanisms, experimental validation, and application data, helping researchers better understand how this system supports bispecific antibody development.
The white paper explains how GM-C41979 was engineered to stably express PD-1 and the trimeric IL-2 receptor complex (CD25/CD122/CD132), enabling accurate measurement of IL-2 pathway activation through a luciferase reporter signal. Comparative assays demonstrate its strong, dose-dependent, and PD-1-specific response, confirming the model’s precision in mimicking PD-1⁺ effector T-cell signaling.
By integrating immune checkpoint and cytokine pathways within a single platform, GM-C41979 offers a standardized and biologically relevant solution for preclinical analysis of PD-1–IL-2v fusion therapeutics. This white paper serves as a valuable reference for scientists seeking reliable tools to accelerate immuno-oncology research and translational development.
